Published in Pigment Cell Melanoma Res on April 01, 2008
Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal (2009) 2.33
Asbestos, lung cancers, and mesotheliomas: from molecular approaches to targeting tumor survival pathways. Am J Respir Cell Mol Biol (2010) 2.04
Notch1 is an effector of Akt and hypoxia in melanoma development. J Clin Invest (2008) 1.89
Melanocytes as instigators and victims of oxidative stress. J Invest Dermatol (2014) 1.13
The cinnamon-derived Michael acceptor cinnamic aldehyde impairs melanoma cell proliferation, invasiveness, and tumor growth. Free Radic Biol Med (2008) 1.10
Aberrant DNA hypermethylation patterns lead to transcriptional silencing of tumor suppressor genes in UVB-exposed skin and UVB-induced skin tumors of mice. Carcinogenesis (2010) 1.07
GLO1 overexpression in human malignant melanoma. Melanoma Res (2010) 0.99
Peroxiredoxin 3 is a redox-dependent target of thiostrepton in malignant mesothelioma cells. PLoS One (2012) 0.99
BI-69A11-mediated inhibition of AKT leads to effective regression of xenograft melanoma. Pigment Cell Melanoma Res (2009) 0.98
Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell Mol Life Sci (2012) 0.96
The redox antimalarial dihydroartemisinin targets human metastatic melanoma cells but not primary melanocytes with induction of NOXA-dependent apoptosis. Invest New Drugs (2011) 0.91
Antimelanoma activity of the redox dye DCPIP (2,6-dichlorophenolindophenol) is antagonized by NQO1. Biochem Pharmacol (2009) 0.91
RGS-GAIP-interacting protein controls breast cancer progression. Mol Cancer Res (2010) 0.90
The role of the hippo pathway in melanocytes and melanoma. Front Oncol (2013) 0.90
Characterization of NADPH oxidase 5 expression in human tumors and tumor cell lines with a novel mouse monoclonal antibody. Free Radic Biol Med (2013) 0.90
Dual effect of oxidative stress on leukemia cancer induction and treatment. J Exp Clin Cancer Res (2014) 0.88
Thiostrepton is an inducer of oxidative and proteotoxic stress that impairs viability of human melanoma cells but not primary melanocytes. Biochem Pharmacol (2012) 0.88
Mitochondrial-targeted nitroxides disrupt mitochondrial architecture and inhibit expression of peroxiredoxin 3 and FOXM1 in malignant mesothelioma cells. J Cell Physiol (2013) 0.86
Conserved expression signatures between medaka and human pigment cell tumors. PLoS One (2012) 0.84
Ultrasound molecular imaging of secreted frizzled related protein-2 expression in murine angiosarcoma. PLoS One (2014) 0.83
MCAM, as a novel receptor for S100A8/A9, mediates progression of malignant melanoma through prominent activation of NF-κB and ROS formation upon ligand binding. Clin Exp Metastasis (2016) 0.82
Peroxiredoxin 3 levels regulate a mitochondrial redox setpoint in malignant mesothelioma cells. Redox Biol (2014) 0.82
Disabling Mitochondrial Peroxide Metabolism via Combinatorial Targeting of Peroxiredoxin 3 as an Effective Therapeutic Approach for Malignant Mesothelioma. PLoS One (2015) 0.81
Updates of reactive oxygen species in melanoma etiology and progression. Arch Biochem Biophys (2014) 0.81
The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Med Chem (2014) 0.79
Application of angiogenesis to clinical dermatology. Adv Dermatol (2008) 0.79
Solenopsin A and analogs exhibit ceramide-like biological activity. Vasc Cell (2015) 0.79
Honokiol bis-dichloroacetate (Honokiol DCA) demonstrates activity in vemurafenib-resistant melanoma in vivo. Oncotarget (2016) 0.79
RedOx status, proteasome and APEH: insights into anticancer mechanisms of t10,c12-conjugated linoleic acid isomer on A375 melanoma cells. PLoS One (2013) 0.76
A Phase II Randomized Placebo-Controlled Trial of Oral N-acetylcysteine for Protection of Melanocytic Nevi against UV-Induced Oxidative Stress In Vivo. Cancer Prev Res (Phila) (2016) 0.75
Immune biomarkers are more accurate in prediction of survival in ulcerated than in non-ulcerated primary melanomas. Cancer Immunol Immunother (2015) 0.75
PHIPing out: a genetic basis for tumor ulceration. J Invest Dermatol (2014) 0.75
Alterations in the Reactive Oxygen Species in Peripheral Blood of Chronic Myeloid Leukaemia Patients from Northern India. J Clin Diagn Res (2017) 0.75
Peroxisome proliferation-associated control of reactive oxygen species sets melanocortin tone and feeding in diet-induced obesity. Nat Med (2011) 3.09
Honokiol, a small molecular weight natural product, inhibits angiogenesis in vitro and tumor growth in vivo. J Biol Chem (2003) 2.44
Overexpression of Akt converts radial growth melanoma to vertical growth melanoma. J Clin Invest (2007) 2.22
Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin Cancer Res (2002) 2.18
Targeted therapy of oral hairy leukoplakia with gentian violet. J Am Acad Dermatol (2008) 2.17
A key role for NOX4 in epithelial cell death during development of lung fibrosis. Antioxid Redox Signal (2011) 1.79
Pharmacologic blockade of angiopoietin-2 is efficacious against model hemangiomas in mice. J Invest Dermatol (2006) 1.72
Fulvene-5 potently inhibits NADPH oxidase 4 and blocks the growth of endothelial tumors in mice. J Clin Invest (2009) 1.68
Honokiol activates AMP-activated protein kinase in breast cancer cells via an LKB1-dependent pathway and inhibits breast carcinogenesis. Breast Cancer Res (2012) 1.65
Honokiol, a multifunctional antiangiogenic and antitumor agent. Antioxid Redox Signal (2009) 1.53
Keloids demonstrate high-level epidermal expression of vascular endothelial growth factor. J Am Acad Dermatol (2004) 1.52
Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells. Clin Cancer Res (2008) 1.43
Malignant transformation of melanocytes to melanoma by constitutive activation of mitogen-activated protein kinase kinase (MAPKK) signaling. J Biol Chem (2003) 1.39
A modified cysteinyl-labeling assay reveals reversible oxidation of protein tyrosine phosphatases in angiomyolipoma cells. Proc Natl Acad Sci U S A (2008) 1.33
Honokiol potentiates apoptosis, suppresses osteoclastogenesis, and inhibits invasion through modulation of nuclear factor-kappaB activation pathway. Mol Cancer Res (2006) 1.32
Reactive oxygen-induced carcinogenesis causes hypermethylation of p16(Ink4a) and activation of MAP kinase. Mol Med (2002) 1.25
Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors. Clin Cancer Res (2010) 1.25
Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma. Proc Natl Acad Sci U S A (2004) 1.22
Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer (2007) 1.19
Honokiol is a potent scavenger of superoxide and peroxyl radicals. Biochem Pharmacol (2008) 1.17
Honokiol, a natural plant product, inhibits inflammatory signals and alleviates inflammatory arthritis. J Immunol (2007) 1.16
Gentian violet: a 19th century drug re-emerges in the 21st century. Exp Dermatol (2013) 1.13
AKT1 overexpression in endothelial cells leads to the development of cutaneous vascular malformations in vivo. Arch Dermatol (2007) 1.12
Mammalian target of rapamycin (mTOR) is activated in cutaneous vascular malformations in vivo. Lymphat Res Biol (2007) 1.12
Secreted frizzle-related protein 2 stimulates angiogenesis via a calcineurin/NFAT signaling pathway. Cancer Res (2009) 1.12
Anti-invasive adjuvant therapy with imipramine blue enhances chemotherapeutic efficacy against glioma. Sci Transl Med (2012) 1.12
Transgenic expression of dominant negative tuberin through a strong constitutive promoter results in a tissue-specific tuberous sclerosis phenotype in the skin and brain. J Biol Chem (2004) 1.04
Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo. Clin Cancer Res (2008) 1.03
Efficacy of topical application of eosin for ulcerated hemangiomas. J Am Acad Dermatol (2009) 1.03
Metabotropic glutamate receptor-dependent long-term depression is impaired due to elevated ERK signaling in the ΔRG mouse model of tuberous sclerosis complex. Neurobiol Dis (2011) 1.03
Effectiveness of gentian violet and similar products commonly used to treat pyodermas. Dermatol Clin (2011) 1.01
Tuberous sclerosis complex suppression in cerebellar development and medulloblastoma: separate regulation of mammalian target of rapamycin activity and p27 Kip1 localization. Cancer Res (2009) 1.01
Expression of the neural stem cell markers NG2 and L1 in human angiomyolipoma: are angiomyolipomas neoplasms of stem cells? Mol Med (2007) 1.01
Angiomotin expression promotes hemangioendothelioma invasion. Oncogene (2004) 0.99
Combination therapy of imiquimod and gentian violet for cutaneous melanoma metastases. J Am Acad Dermatol (2012) 0.98
Disruption of the mitochondrial thioredoxin system as a cell death mechanism of cationic triphenylmethanes. Free Radic Biol Med (2011) 0.98
Expression of Wilms tumor 1 gene distinguishes vascular malformations from proliferative endothelial lesions. Arch Dermatol (2005) 0.97
Synthesis and biological evaluation of aromatic enones related to curcumin. Bioorg Med Chem (2005) 0.97
Infectious angiogenesis: Bartonella bacilliformis infection results in endothelial production of angiopoetin-2 and epidermal production of vascular endothelial growth factor. Am J Pathol (2003) 0.96
Targeting NADPH oxidases for the treatment of cancer and inflammation. Cell Mol Life Sci (2012) 0.96
Honokiol, a natural biphenyl, inhibits in vitro and in vivo growth of breast cancer through induction of apoptosis and cell cycle arrest. Int J Oncol (2007) 0.96
Rapamycin (sirolimus) as a steroid-sparing agent in dermatomyositis. J Am Acad Dermatol (2005) 0.96
Curcumin as an inhibitor of angiogenesis. Adv Exp Med Biol (2007) 0.95
The natural product honokiol preferentially inhibits cellular FLICE-inhibitory protein and augments death receptor-induced apoptosis. Mol Cancer Ther (2008) 0.94
Weight loss-induced calciphylaxis: potential role of matrix metalloproteinases. J Dermatol (2003) 0.94
The role of angiogenesis in the pathogenesis of psoriasis. Autoimmunity (2009) 0.93
Molecular pathogenesis of vascular anomalies: classification into three categories based upon clinical and biochemical characteristics. Lymphat Res Biol (2003) 0.92
Tuberous sclerosis-associated neoplasms express activated p42/44 mitogen-activated protein (MAP) kinase, and inhibition of MAP kinase signaling results in decreased in vivo tumor growth. Clin Cancer Res (2003) 0.91
Angiogenesis in cutaneous lesions of leprosy: implications for treatment. Arch Dermatol (2007) 0.91
Facile purification of honokiol and its antiviral and cytotoxic properties. J Med Chem (2006) 0.90
Immunosuppression may be present within condyloma acuminata. J Am Acad Dermatol (2008) 0.90
gli-1 Oncogene is highly expressed in granulomatous skin disorders, including sarcoidosis, granuloma annulare, and necrobiosis lipoidica diabeticorum. Arch Dermatol (2005) 0.90
Malignant transformation of human cells by constitutive expression of platelet-derived growth factor-BB. J Biol Chem (2005) 0.90
Design, synthesis, and biological evaluation of angiogenesis inhibitors: aromatic enone and dienone analogues of curcumin. Bioorg Med Chem Lett (2003) 0.89
Reductions in funding for medical research. JAMA (2013) 0.89
Inactivation of NADPH oxidases NOX4 and NOX5 protects human primary fibroblasts from ionizing radiation-induced DNA damage. Radiat Res (2015) 0.88
Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors. Expert Rev Anti Infect Ther (2007) 0.88
The natural product honokiol inhibits calcineurin inhibitor-induced and Ras-mediated tumor promoting pathways. Cancer Lett (2013) 0.88
Enhanced MCP-1 release by keloid CD14+ cells augments fibroblast proliferation: role of MCP-1 and Akt pathway in keloids. Exp Dermatol (2010) 0.88
Solenopsin A, a venom alkaloid from the fire ant Solenopsis invicta, inhibits quorum-sensing signaling in Pseudomonas aeruginosa. J Infect Dis (2008) 0.86
Synthesis, cytotoxicity, and antiviral activities of new neolignans related to honokiol and magnolol. Bioorg Med Chem Lett (2007) 0.86
PSK and Trx80 inhibit B-cell growth in EBV-infected cord blood mononuclear cells through T cells activated by the monocyte products IL-15 and IL-12. Blood (2004) 0.86
The antidepressant sertraline downregulates Akt and has activity against melanoma cells. Pigment Cell Melanoma Res (2008) 0.85
Maspin expression, angiogenesis, prognostic parameters, and outcome in malignant melanoma. J Am Acad Dermatol (2009) 0.85
Targeting the intrinsic inflammatory pathway: honokiol exerts proapoptotic effects through STAT3 inhibition in transformed Barrett's cells. Am J Physiol Gastrointest Liver Physiol (2012) 0.85
Efficacy of rapamycin in scleroderma: a case study. Lymphat Res Biol (2008) 0.84
Tumor necrosis factor-related apoptosis-inducing ligand can induce apoptosis in subsets of premalignant cells. Am J Pathol (2004) 0.84
Phosphorylation by mitogen-activated protein kinase mediates the hypoxia-induced turnover of the TAL1/SCL transcription factor in endothelial cells. J Biol Chem (2002) 0.82
Cutaneous lesions of secondary syphilis are highly angiogenic. J Am Acad Dermatol (2003) 0.82
Combination therapy of doxycycline and topical tacrolimus for venous ulcers. Arch Dermatol (2005) 0.81
A nonsteroidal alternative to impetiginized eczema in the emergency room. J Am Acad Dermatol (2010) 0.81
Rapid improvement of nephrogenic systemic fibrosis with rapamycin therapy: possible role of phospho-70-ribosomal-S6 kinase. J Am Acad Dermatol (2010) 0.81
Honokiol stimulates osteoblastogenesis by suppressing NF-κB activation. Int J Mol Med (2011) 0.81
The duality of angiogenesis: implications for therapy of human disease. J Invest Dermatol (2006) 0.81
Shb gene knockdown increases the susceptibility of SVR endothelial tumor cells to apoptotic stimuli in vitro and in vivo. J Invest Dermatol (2007) 0.81
Regulation of endothelial cell differentiation and transformation by H-Ras. Exp Cell Res (2003) 0.80
Honokiol induces cell cycle arrest and apoptosis via inhibition of survival signals in adult T-cell leukemia. Biochim Biophys Acta (2012) 0.80
Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia. Vasc Cell (2012) 0.80
Gentian violet is safe. J Am Acad Dermatol (2009) 0.80
Honokiol inhibits androgen receptor activity in prostate cancer cells. Prostate (2013) 0.80
Wilms tumor 1 expression present in most melanomas but nearly absent in nevi. Arch Dermatol (2006) 0.80
The antioxidant paradox: what are antioxidants and how should they be used in a therapeutic context for cancer. Future Med Chem (2014) 0.79
Application of angiogenesis to clinical dermatology. Adv Dermatol (2008) 0.79
High level expression of angiopoietin-2 in human abscesses. J Am Acad Dermatol (2011) 0.78
Novel antiangiogenic agents in dermatology. Arch Biochem Biophys (2010) 0.78
Apolipoprotein D is down-regulated during malignant transformation of neurofibromas. Hum Pathol (2005) 0.77
In vivo Gram staining of tinea versicolor. JAMA Dermatol (2013) 0.76
Melanomas reveal their nakedness: uncovered by interferon alfa. Arch Dermatol (2009) 0.75
Disseminated pyoderma gangrenosum: role for vascular endothelial growth factor and hypoxia inducible factor-2. J Am Acad Dermatol (2009) 0.75
Role of manganese superoxide dismutase in cancer. Nat Med (2003) 0.75
Honokiol Increases CD4+ T Cell Activation and Decreases TNF but Fails to Improve Survival Following Sepsis. Shock (2017) 0.75
Effective local anesthesia for onabotulinumtoxin A injections to treat hyperhidrosis associated with traumatic amputation. Dermatol Online J (2016) 0.75
Ulcerative granulomatous mycosis fungoides. Skinmed (2010) 0.75